Comprehensive results of ESG401, a TROP2-targeting ADC: Updated phase 1 analysis in advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results